Laboratoires CTRS Revenue and Competitors
Estimated Revenue & Valuation
- Laboratoires CTRS's estimated annual revenue is currently $2.4M per year.
- Laboratoires CTRS's estimated revenue per employee is $201,000
Employee Data
- Laboratoires CTRS has 12 Employees.
- Laboratoires CTRS grew their employee count by -29% last year.
Laboratoires CTRS's People
Name | Title | Email/Phone |
---|
Laboratoires CTRS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Laboratoires CTRS?
CTRS is a French pharmaceutical company with a strong and growing international presence. Our main focus is rare diseases. Our ambition is to develop and commercialize treatments for patients with high unmet medical needs. Since our creation, we have been committed to developing treatments which will change the life of patients. We work in close collaboration with academic institutions to offer patients access to the therapies most adapted to their needs. Guided by science and research, the patient is at the core of everything we do. CTRS is a team of 16 people : they are the fundamental element of the company. Their career, their experiences and their personalities have made CTRS a unique company. We all have the same values and the same level of commitment to patients and to improving their quality of life.
keywords:N/AN/A
Total Funding
12
Number of Employees
$2.4M
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 12 | 20% | N/A |
#2 | $0.8M | 13 | -24% | N/A |
#3 | $1.2M | 14 | -7% | N/A |
#4 | $1.3M | 15 | -17% | N/A |
#5 | $2.2M | 18 | 6% | N/A |